Zydus Lifesciences has informed that the Board of Directors at their meeting held today, November 11, 2022, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / half year ended on September 30, 2022. In this regard, the company enclosed the following: the Unaudited Financial Results (standalone and consolidated) for the quarter / half year ended on September 30, 2022, reviewed by the Audit Committee and taken on record by the Board of Directors pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations); the Limited Review Reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the Unaudited Financial Results (standalone and consolidated) of the Company for the quarter / half year ended on September 30, 2022 pursuant to regulation 33 of the Listing Regulations; press release proposed to be published in the newspapers in the matter of Unaudited Financial Results for the quarter / half year ended on September 30, 2022.
The above information is a part of company’s filings submitted to BSE.
